A prothrombotic state is one of the hallmarks of malignancy and a major contributor to morbidity and mortality in cancer patients. Tissue factor (TF) is often overexpressed in malignancy and is a prime candidate in predicting the hypercoagulable state. Moreover, increased number of TF-exposing microparticles (MPs) in cancer patients may contribute to venous thromboembolism (VTE). We have conducted a prospective cohort study to determine whether elevated TF antigen, TF activity and TF associated to MPs (MPs-TF) are predictive of VTE and mortality in cancer patients. The studied population consisted of 252 cancer patients and 36 healthy controls. TF antigen and activity and MPs-TF were determined by ELISA and chromogenic assays. During a median follow-up of 10 months, 40 thrombotic events were recorded in 34 patients (13.5%), and 73 patients (28.9%) died. TF antigen and activity were significantly higher in patients than in controls (p<0.01) mainly in patients with advanced stages, whereas no differences were observed for TF activity of isolated MPs. We did not find a statistically significant association of TF variables with the risk of VTE. Multivariate analysis adjusting for age, sex, type of cancer and other confounding variables showed that TF activity (p<0.01) and MPs-TF activity (p<0.05) were independently associated with mortality. In conclusion, while TF variables were not associated with future VTE in cancer patients, we found a strong association of TF and MPs-TF activity with mortality, thus suggesting they might be good prognostic markers in cancer patients.
1
Font C,
Farrus B,
Vidal L.
et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol 2011; 22: 2101-2106.
2
Di Nisio M,
Ferrante N,
De Tursi M.
et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104: 1049-1054.
3
Cronin-Fenton DP,
Sondergaard F,
Pedersen LA.
et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103: 947-953.
5
Monreal M,
Falga C,
Valdes M.
et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 04: 1950-1956.
12
Press JZ,
Reyes M,
Pitteri SJ.
et al. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer 2012; 22: 546-552.
13
Manly DA,
Wang J,
Glover SL.
et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res 2010; 125: 511-512.
14
Tesselaar ME,
Romijn FP,
Van Der Linden IK.
et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 05: 520-527.
15
Khorana AA,
Ahrendt SA,
Ryan CK.
et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
16
Zwicker JI,
Liebman HA,
Neuberg D.
et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
17
Tesselaar ME,
Romijn FP,
van der Linden IK.
et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 07: 1421-1423.
18
Campello E,
Spiezia L,
Radu CM.
et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127: 473-477.
19
Thaler J,
Ay C,
Pabinger I.
Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hamostaseologie 2012; 32: 127-131.
20
van Doormaal F,
Kleinjan A,
Berckmans RJ.
et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108: 160-165.
21
Steppich BA,
Hassenpflug M,
Braun SL.
et al. Circulating tissue factor and microparticles are not increased in patients with deep vein thrombosis. Vasa 2011; 40: 117-122.
22
Martinez de Lizarrondo S,
Roncal C,
Calvayrac O.
et al. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012; 32: 1477-1487.
23
Davila M,
Amirkhosravi A,
Coll E.
et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 06: 1517-1524.
25
Blom JW,
Vanderschoot JP,
Oostindier MJ.
et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 04: 529-535.
26
Ay C,
Vormittag R,
Dunkler D.
et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-4129.
27
Yamamoto M,
Yoshinaga K,
Matsuyama A.
et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology 2012; 83: 10-15.
28
Sartori MT,
Della Puppa A,
Ballin A.
et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011; 104: 225-231.
29
Auwerda JJ,
Yuana Y,
Osanto S.
et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105: 14-20.
30
Tilley RE,
Holscher T,
Belani R.
et al. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 2008; 122: 604-609.
31
Haubold K,
Rink M,
Spath B.
et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101: 1147-1155.
33
Thaler J,
Ay C,
Mackman N.
et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10: 1363-1370.
34
Diamant M,
Nieuwland R,
Pablo RF.
et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
35
Wang JG,
Geddings JE,
Aleman MM.
et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119: 5543-5552.
36
Davila M,
Amirkhosravi A,
Coll E.
et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Throm Haemost 2008; 06: 1517-1524.
37
Garnier D,
Magnus N,
Lee T.
et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem 2012; 287: 43565-43572.
38
Han LY,
Landen Jr. CN,
Kamat AA.
et al. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 2006; 24: 755-761.
39
Ueno T,
Toi M,
Koike M.
et al. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-170.
